{"schema_version":"secwatch.filing_event.v1","accession":"0001200375-23-000022","form_type":"8-K","ticker":"CDXS","cik":"0001200375","company_name":"CODEXIS, INC.","filed_at":"2023-07-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.334954+00:00","generated_at":"2026-06-13T05:26:02.875878+00:00","sec_items":["2.02","2.05","2.06","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Codexis reduces headcount 25%, extends cash runway to mid-2026; Q2 preliminary revenue $21-22M","bullets":["Workforce reduction of ~25% (approx. $2.9M expense in Q3 2023); expects completion by Sep 30, 2023.","Discontinuing investment in Biotherapeutics programs, consolidating to Redwood City HQ.","Preliminary Q2 2023 total revenue $21-22M (product $11-12M, R&D $10M); cash $92.1M.","Reiterates 2023 product revenue guidance $30-35M; lowers R&D revenue guidance to $21-24M (from $28-33M).","Expects cash runway to mid-2026; anticipates Pharma Manufacturing growth in 2024; ECO Synthesis demo by end of 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001200375-23-000022","json":"https://secwatch.observer/filing/0001200375-23-000022.json","markdown":"https://secwatch.observer/filing/0001200375-23-000022.md","text":"https://secwatch.observer/filing/0001200375-23-000022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1200375/000120037523000022/0001200375-23-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1200375/000120037523000022/cdxs-20230720.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T05:26:02.875878+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"92a93e58d275ddaf0dc3211881360134d579b72e","claim":"CODEXIS, INC. updated its the quarter ended June 30, 2023 guidance (reaffirmed).","evidence_excerpt":"On July 20, 2023 Codexis, Inc. (the “Company”) announced certain of its preliminary unaudited financial results for the quarter ended June 30, 2023, reiterated and provided new financial guidance","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1200375/000120037523000022/0001200375-23-000022-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"6d94cb1d1f959e6c8aa5ee30269fe4e6fe8c6c9e","claim":"CODEXIS, INC. announced a restructuring with charges of approximately $2.9 million (approximately 25%).","evidence_excerpt":"On July 20, 2023, in alignment with its enhanced strategic focus, the Company publicly announced and informed its employees that it was implementing a workforce reduction of approximately 25%. This measure was implemented in support of the Company’s organizational streamlining to focus on the continued advancement and commercialization of its Enzyme-Catalyzed Oligonucleotide (ECO) SynthesisTM platform and its highly complementary Pharmaceutical Manufacturing business. The Company expects the payment of post-employment benefits to impacted employees, as well as the payment of other expenses such as related tax costs, will result in the Company recording an expense of approximately $2.9 million.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1200375/000120037523000022/0001200375-23-000022-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $2.9 million"},{"label":"Headcount","value":"approximately 25%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}